Philippe Beaune

Philippe Beaune

Auto-generated profile, based on publicly available information

Philippe Beaune

INSERM UMR-S 1147, Paris, France

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1990 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
RPRaimund Peter
Raimund Peter
RBRonald Boecker
Ronald Boecker
PBPhilippe H. Beaune
Philippe H. Beaune
MIMasahiko Iwasaki
Masahiko Iwasaki
FGF. Peter Guengerich
F. Peter Guengerich
CYChung S. Yang
Chung S. Yang

1 January 2007 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
ZBZoe E. Barter
Zoe E. Barter
MBMartin K. Bayliss
Martin K. Bayliss
PBPhilip H. Beaune
Philip H. Beaune
ABAlan R. Boobis
Alan R. Boobis
DCDavid J. Carlile
David J. Carlile
ARAmin Rostami-Hodjegan
Amin Rostami-Hodjegan
Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity (HPGL) per gram of liver, generally with no consideration of the extent of their inter-individual variability. We have collated and analysed data from a number of sources, to provide weighted meangeo values of human MPPGL and HPGL of 32 mg g-1 (95% Confidence Interval (CI); 29 - 34 mg.g-1) and 99 x 106 cells.g-1 (95% CI; 74 131 mg.g-1), respectively. Although inter-individual variability in values of MPPGL and HPGL was statistically significant, gender, smoking or alcohol consumption could not be detected as significant covariates by multiple linear regression. However, there was a weak but statistically significant inverse relationship between age and both MPPGL and HPGL. These findings indicate the importance of considering differences between study populations when forecasting in vivo pharmacokinetic behaviour. Typical clinical pharmacology studies, particularly in early drug development, use young, fit, healthy male subjects of around 30 years of age. In contrast, the average age of patients for many diseases is about 60 years of age. The relationship between age and MPPGL observed in this study estimates values of 40 mg.g-1 for a 30 year old individual and 31 mg.g-1 for a 60 year old individual. Investigators may wish to consider the reported covariates in the selection of scaling factors appropriate for the population in which estimates of clearance are being predicted. Further studies are required to clarify the influence of age (especially in paediatric subjects), donor source and ethnicity on values of MPPGL and HPGL. In the meantime, we recommend that the estimates (and their variances) from the current meta-analysis be used when predicting in vivo kinetic parameters from in vitro data.

1 October 1993 in Molecular Pharmacology
Verified
Journal Article
Closed access
ZAZ Abdel-Razzak
Z Abdel-Razzak
PLPascal Loyer
Pascal Loyer
AFAlain Fautrel
Alain Fautrel
JGJ C Gautier
J C Gautier
Laurent CorcosLaurent Corcos
Laurent Corcos
AGA Guillouzo
A Guillouzo

1 September 2007 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
IBIvan Bieche
Ivan Bieche
CNCéline Narjoz
Céline Narjoz
TATarik Asselah
Tarik Asselah
SVSophie VACHER
Sophie VACHER
PMPatrick Marcellin
Patrick Marcellin
IWIsabelle de Waziers
Isabelle de Waziers
Objective The aim of this work was to study simultaneously the expression profile of the 23 CYP mRNAs of CYP1, CTP2 and CYP3 families in 22 different human tissues namely adrenal gland, bladder, bone marrow, colon, fetal liver, heart, kidney, liver, lung, mammary gland, ovary, placenta, prostate, salivary gland, skeletal muscle, small intestine, spleen, testis, thymus, thyroid, trachea and uterus. Methods Analysis of the mRNA levels of each of these CYP isoforms was performed on total RNA from pooled specimens of human organs using reverse transcriptase-PCR-based CYP mRNA assays previously validated for their sensitivity and their specificity. Results Our results confirmed previously reported data in the literature concerning isoforms expression in the most currently studied tissues. Moreover, they provided a great deal of new information, mainly about the expression of mRNA of little-known CYP isoforms. Among the 23 CYP isoforms studied, 12 were mainly hepatic (CYP1A2, 2A6, 2A7, 2A13, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4 and 3A43). Two CYP mRNAs were predominantly expressed in several extrahepatic tissues: CYP1B1 mRNA was the predominant CYP in seven extrahepatic tissues (bone marrow, kidney, mammary gland, prostate, spleen, thyroid and uterus) and CYP2J2 in four extrahepatic tissues (heart, placenta, salivary gland and skeletal muscle). Finally, some CYPs were nearly exclusively expressed in only one extrahepatic tissue. CYP2R1 was found in testis, CYP2U1 in the thymus and CYP2F1 in the respiratory tract (lung and trachea). Conclusion This description will broaden the understanding of the physiological functions of these CYPs.

15 March 2005 in Blood
Verified
Journal Article
Closed access
PDF file
LBLaurent Bodin
Laurent Bodin
CVCéline Verstuyft
Céline Verstuyft
DTDavid-Alexandre Tregouet
David-Alexandre Tregouet
ARAnnie Robert
Annie Robert
LDLiliane Dubert
Liliane Dubert
MLMarie-Anne Loriot
Marie-Anne Loriot
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability in the response to acenocoumarol among 222 healthy volunteers after a single oral dose. Associations between a pharmacodynamic index (reduction in factor VII activity and international normalized ratio [INR] change) and several genetic polymorphisms (VKORC1: –4931T>C, –4451C>A, –2659G>C, –1877A>G, –1639G>A, 497C>G, 1173C>T, and CYP2C9*3) were investigated using haplotype and univariate analyses. VKORC1 haplotypes were associated with the pharmacologic response, and this association can be explained only by the effect of the –1639G>A polymorphism (or alternatively by 1173C>T, which is in complete association with it). Indeed, it explains about one third of the variability of the pharmacologic response (37% of factor VII decrease and 30% of INR change). Moreover, the previously observed effect of the CYP2C9*3 allele is independent of the VKORC1 gene effect. These 2 polymorphisms account for up to 50% of the interindividual variability. The simple genotyping of 2 single-nucleotide polymorphisms (SNPs), VKORC1 –1639G>A or 1173C>T and the CYP2C9*3 polymorphisms, could thus predict a high risk of overdose before initiation of anticoagulation with acenocoumarol, and provide a safer and more individualized anticoagulant therapy.

1 October 1989 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
CGC Ged
C Ged
JRJm Rouillon
Jm Rouillon
LPL Pichard
L Pichard
JCJ Combalbert
J Combalbert
NBN Bressot
N Bressot
PMP Maurel
P Maurel
1. Urinary excretion of 6 beta‐hydroxycortisol, hepatic microsomal cortisol 6 beta‐hydroxylase and the specific content of several forms of cytochrome P450 were measured in 8 to 14 patients before and after treatment with rifampicin (600 mg orally per day for 4 days). 2. Rifampicin treatment produced an average five fold increase in daily excretion of urinary 6 beta‐hydroxycortisol. 3. Cortisol 6 beta‐ hydroxylase activity increased from 15 +/‐ 6 pmol min‐1 mg‐1 in organ donors (considered as 'control subjects') to 87 +/‐ 31 pmol min‐1 mg‐1 in rifampicin treated patients. 4. Among three forms of human P450 (P450IA, IIC and IIIA), (1), (2), measured by Western blots, only P450IIIA was significantly induced by the antibiotic. 5. Only antibodies against P450IIIA selectively inhibited cortisol 6 beta‐ hydroxylase in human liver microsomes. 6. Cortisol 6 beta‐hydroxylase was correlated with P450IIIA specific content. 7. The urinary level of 6 beta‐hydroxycortisol correlated with liver microsomal cortisol 6 beta‐ hydroxylase and P450IIIA specific content. 8. We conclude that P450IIIA is predominantly responsible for cortisol 6 beta‐hydroxylase activity in human liver microsomes and that urinary 6 beta‐hydroxycortisol is a marker of the induction of this cytochrome P450.